IP key to the rise and rise of the Chinese pharma sector

Could China produce a home-grown Pfizer or Bayer within the next few years? That may be debatable, but what is not in doubt is that the country is investing strongly in the development of its domestic pharmaceutical industry: crucially, IP…

Get unlimited access to all IAM content